ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
Dow Jones
38,239.66
0.40%
US Dollar vs MXN
17.1601
0.00%
Brent Oil
88.165
0.00%
Bitcoin
63,433.53
-0.48%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. INmune Bio Inc (INMB)

  7. INmune Bio Inc (INMB) Noticias

INMB INmune Bio Inc

11.29
0.45 (4.15%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
INmune Bio Inc INMB NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.45 4.15% 11.29 18:38:49
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
10.83 10.83 11.73 11.29 10.84
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
25/4/202408:00GLOBEINmune Bio Inc. Announces $9.7 Million Registered Direct..
23/4/202407:00GLOBEINmune Bio Inc. Announces 24-Month Stability Validation of..
22/4/202407:00GLOBEINmune Bio Inc. Raises Approximately $4.8 Million in Gross..
08/4/202407:00GLOBEINmune Bio Inc. Presents Data on INB03’s Role as an Immune..
28/3/202415:01GLOBEINmune Bio Inc. Announces Year End 2023 Results and Provides..
26/3/202415:01GLOBEINmune Bio Inc. to Report Fourth Quarter 2023 Financial..
13/3/202407:00GLOBEINmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives..
05/3/202407:00GLOBEINmune Bio Reports Significant EEG Improvement in..
12/2/202408:00GLOBEINmune Bio to Participate in the Oppenheimer 34th Annual..
06/2/202408:00GLOBEINmune Bio to Participate in Baird’s Biotech Discovery..
30/1/202407:02EDGAR2Form 8-K - Current report
30/1/202407:00GLOBEINmune Bio Announces FDA Removal of Clinical Hold for..
16/1/202407:30GLOBEELEVAI Labs, Inc. Acquires Worldwide License Agreement for..
02/1/202415:00EDGAR2Form 8-K - Current report
02/1/202407:00GLOBEINmune Bio Announces First Patient Dosed in a Phase 1/2..
18/12/202315:15EDGAR2Form 8-K - Current report
18/12/202315:05EDGAR2Form 8-A12B/A - Registration of securities [Section 12(b)]:..
18/12/202315:01EDGAR2Form 8-K - Current report
18/12/202315:01GLOBEINmune Bio Provides Update Regarding Global Alzheimer’s..
29/11/202315:00EDGAR2Form 8-K - Current report
29/11/202307:00GLOBEINmune Bio Inc. Demonstrates that INB03 Enhances the Uptake..
27/11/202315:00EDGAR2Form 8-K - Current report
27/11/202307:00GLOBEINmune Bio Receives EMA’s Authorization in France and Spain..
15/11/202315:13EDGAR2Form 8-K - Current report
15/11/202308:00GLOBEINmune Bio Inc. Announces Expansion of Phase II Clinical..
13/11/202310:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/11/202315:13EDGAR2Form 8-K - Current report
01/11/202315:10GLOBEINmune Bio Inc. Announces Third Quarter 2023 Results and..
01/11/202315:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
31/10/202315:25EDGAR2Form 8-K - Current report
31/10/202307:00GLOBEINmune Bio Inc. Patent Claims Covering INB16 Cell Line and..
30/10/202308:07GLOBEINmune Bio Inc. Presents Preclinical Data at SITC 2023..
17/10/202307:00GLOBEINmune Bio Inc. Presents New Biomarker and Feasibility Data..
16/10/202308:00GLOBEINmune Bio Inc. to Report Third Quarter 2023 Financial..
07/9/202308:10EDGAR2Form 8-K - Current report
07/9/202308:00GLOBEINmune Bio Inc. to Present at Baird Global Healthcare..
05/9/202315:00EDGAR2Form 8-K - Current report
05/9/202307:00GLOBEINmune Bio Inc. Announces Approval of Clinical Trial..
16/8/202315:41EDGAR2Form 8-K - Current report
16/8/202315:39EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
08/8/202315:01EDGAR2Form 8-K - Current report
07/8/202315:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202315:00GLOBEINmune Bio Inc. Announces Second Quarter 2023 Results and..
02/8/202305:02EDGAR2Form 8-K - Current report
01/8/202307:00GLOBEINmune Bio Inc. to Present at the BTIG Virtual ..
31/7/202307:00GLOBEINmune Bio, Inc. to Report Second Quarter 2023 Financial..
27/7/202315:43EDGAR2Form 8-K - Current report
14/7/202315:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/7/202315:00EDGAR2Form 8-K - Current report
12/7/202312:23EDGAR2Form 144 - Report of proposed sale of securities

Su Consulta Reciente

NASDAQ
INMB
INmune Bio
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados